HALO
NASDAQ · Biotechnology
Halozyme Therapeutics Inc
$103.63
-19.33 (-15.72%)
Performance
1D
+0.00%
1W
-19.64%
1M
-5.65%
3M
+0.98%
6M
+56.05%
1Y
+51.86%
YTD
+47.39%
Open$117.03
Previous Close$122.96
Day High$118.26
Day Low$102.52
52W High$134.00
52W Low$61.23
Volume—
Avg Volume1.88M
Market Cap13.96B
P/E Ratio33.74
EPS$3.35
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$115.19
Below
SMA 200
$84.66
Above
RSI (14)
26.6
Oversold
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
16 analysts
Price Target
-79.7% upside
Current
$103.63
$103.63
Target
$21.02
$21.02
$15.29
$21.02 avg
$24.22
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.52B | 1.18B | 1.30B |
| Net Income | 344.42M | 241.45M | -74,995,325 |
| Profit Margin | 22.7% | 21.6% | -5.8% |
| EBITDA | 587.13M | 434.47M | -91,476,031 |
| Free Cash Flow | — | — | -86,399,966 |
| Rev Growth | +28.4% | +28.4% | +13.4% |
| Debt/Equity | 43.89 | 43.89 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |